Elbadawi Ayman, Naqvi Syed Yaseen, Saad Marwan, Elgendy Islam Y, Mahmoud Ahmed A, Zainal Abir, Megaly Michael, Almahmoud Mohamed F, Altaweel Ahmed, Kleiman Neal, Abbott J Dawn
Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas.
Department of Cardiology, University of Rochester Medical Center, Rochester, NY.
Cardiovasc Revasc Med. 2020 May;21(5):604-609. doi: 10.1016/j.carrev.2019.09.009. Epub 2019 Sep 12.
There is a paucity of data regarding outcomes with transfemoral (TF) versus transapical (TA) access for transcatheter aortic valve replacement (TAVR) in patients with peripheral artery disease (PAD).
We queried the national inpatient sample database (NIS) (2012-2013) to identify patients with PAD who underwent TAVR. We conducted a propensity matching analysis using 25 clinical variables to compare TF-TAVR versus TA-TAVR. The main outcome was in-hospital mortality.
The analysis included 22,349 patients who underwent TAVR, among those 6692 (29.9%) had PAD. In the matched cohort, in-hospital mortality was similar between TF-TAVR and TA-TAVR groups (4.8% vs. 5.1%, OR 0.95; 95%CI 0.74-1.21). TF-TAVR was associated with lower rates of cardiogenic shock (OR 0.64; 95%CI 0.50-0.82), use of mechanical circulatory support (OR 0.56; 95%CI 0.42-0.75), acute kidney injury (OR 0.76; 95%CI 0.67-0.86), hemodialysis (OR 0.51; 95%CI 0.36-0.71), major bleeding (OR 0.72; 95%CI 0.64-0.80), blood transfusion (OR 0.65; 95%CI 0.58-0.73), discharge to a skilled nursing facility (OR 0.61; 95%CI 0.54-0.68) as well as shorter length of hospital stay (8.13 ± 6.76 vs. 10.11 ± 7.80 days) compared with TA-TAVR. However, TF-TAVR was associated with higher rate of vascular complications (11.7% vs. 3.7%, OR 3.40; 95%CI 2.63-4.38), complete heart block (OR 1.52; 95%CI 1.23-1.87), and pacemaker insertion (OR = 1.58; 95%CI: 1.28-1.94). There was no difference between both groups in the rate of cerebrovascular accidents (OR 1.26; 95%CI 0.93-1.72).
In this observational analysis from a large national database, there was no difference in in-hospital mortality between TF-TAVR and TA-TAVR among patients with PAD. Further studies are encouraged to identify the optimal access for TAVR in patients with PAD.
关于经股动脉(TF)与经心尖(TA)入路行导管主动脉瓣置换术(TAVR)治疗外周动脉疾病(PAD)患者的预后数据较少。
我们查询了国家住院患者样本数据库(NIS)(2012 - 2013年),以确定接受TAVR的PAD患者。我们使用25个临床变量进行倾向匹配分析,比较TF-TAVR与TA-TAVR。主要结局是住院死亡率。
分析纳入了22349例行TAVR的患者,其中6692例(29.9%)患有PAD。在匹配队列中,TF-TAVR组和TA-TAVR组的住院死亡率相似(4.8%对5.1%,OR 0.95;95%CI 0.74 - 1.21)。与TA-TAVR相比,TF-TAVR与较低的心源性休克发生率(OR 0.64;95%CI 0.50 - 0.82)、机械循环支持的使用(OR 0.56;95%CI 0.42 - 0.75)、急性肾损伤(OR 0.